|
1
|
Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results.
|
J Clin Oncol
|
2003
|
2.63
|
|
2
|
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
|
Clin Cancer Res
|
2007
|
2.00
|
|
3
|
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
|
J Clin Endocrinol Metab
|
2008
|
1.40
|
|
4
|
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
|
J Clin Oncol
|
2005
|
1.33
|
|
5
|
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
|
Clin Cancer Res
|
2005
|
1.23
|
|
6
|
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
|
Clin Cancer Res
|
2009
|
1.07
|
|
7
|
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.
|
Blood
|
2002
|
1.05
|
|
8
|
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
|
Clin Cancer Res
|
2008
|
1.05
|
|
9
|
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
|
Clin Cancer Res
|
2009
|
1.02
|
|
10
|
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
|
J Natl Cancer Inst
|
2013
|
0.99
|
|
11
|
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
|
Br J Haematol
|
2010
|
0.96
|
|
12
|
G3139 (Genasense) in patients with advanced merkel cell carcinoma.
|
Am J Clin Oncol
|
2009
|
0.90
|
|
13
|
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
|
Clin Cancer Res
|
2010
|
0.87
|
|
14
|
Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
|
J Clin Oncol
|
2007
|
0.86
|
|
15
|
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
|
Cancer Chemother Pharmacol
|
2010
|
0.83
|
|
16
|
A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
|
J Thorac Oncol
|
2009
|
0.80
|
|
17
|
Clinical trials referral resource. Current clinical trials of G3139.
|
Oncology (Williston Park)
|
2003
|
0.76
|
|
18
|
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
|
Leuk Lymphoma
|
2013
|
0.76
|
|
19
|
Clinical trials referral resource. Current clinical trials of molecularly targeted agents in children with cancer, Part 2.
|
Oncology (Williston Park)
|
2002
|
0.75
|
|
20
|
Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer Institute.
|
Future Med Chem
|
2010
|
0.75
|